watching biotechs, gold & silver
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
" I bought at the close today for the run up next week."
Good move- $$$ in the bank, even if not next week.
I'm holding off for the possibility of what may never come; an even more ridiculous low price.
New indications add considerable value and yet the price plunges. Clearly the "efficient market hypothesis" is a crock.
Options expiration explanation is the only plausible one I can see, along with the related manipulation by the big boys.
"Price is what you pay. Value is what you get." Warren Buffett
Someday it will all look different.
Relax BR. Shortly we may get into the range where you like to sell the stock and buy puts.
Ham & eggs, Lox & bagels- NYC venue
"moosedogger, must you copy everything I post?:"
Just trying to help you protect your windfall from ARIA.
"No good deed goes unpunished"
Why so hostile to those of us on the board (the majority) offering to help you?
"....when I buy a stock and it goes underwater almost immediately and stays down there for six months and then suddenly pops above the price I paid for it, I get itchy fingers holding it."
Biotech isn't for you - better stick to funds
"... will have to see if these new shareholders that are part of the massive 40% of the additional new shares want to stick around..."
I think the majority of them are committed, as many have reaped sizable gains already by playing the stock up and down, effectively squeezing to some degree the small traders. While the big boys may have entered at $6.75 or higher, their true cost is lower in many cases due to their activities post dilution.
The real question to me concerns the staying power of the army of retail investors/traders/speculators. How much intestinal fortitude (guts) do they have?
We will see as this exciting story continues to unfold.
Onward and upward.
"....selling pressure now for folks wanting to cash out at even... "
If so, they're still better off than your choice of selling at $6 and buying puts.
Your negativity has been costly indeed.
Why not just eat some crow and apologize to Vid and the board- you'll be better off for it.
Funny us, thinking credibility is something to strive for.
Indeed, it really does take all kinds.
"Curiouser and curiouser" (cried Alice)
Awesome post indeed!!!
"...no one reads the Motley Fool articles anymore..."
Does that mean you no longer believe they must be stopped?
"Why High-Flying Aurinia Pharmaceuticals Stock Could Still Be Dirt Cheap"
"This clinical-stage biopharma stock has a great risk-reward proposition."
"Aurinia reported results from a phase 2 study evaluating voclosporin in treating lupus nephritis (LN) in March. And those results were fantastic. After 48 weeks of treatment, 49% of patients receiving a twice-per-day combination of voclosporin with the current standard of care for LN, mycophenolate mofetil, experienced complete remission. Partial remission came for 69% of patients taking the voclosporin combo."
From our friends at Motley Fool today:
https://www.fool.com/investing/2017/10/13/why-high-flying-aurinia-pharmaceuticals-stock-coul.aspx
Aurinia Receives National Corporate Visionary Award from the Lupus Foundation of America
“We are humbled and thrilled to accept this award,” said Dr. Glickman. “The Foundation’s work is crucial to advancing treatments for this disease, and I am proud of the progress Aurinia is making to contribute to the understanding and treatment of the disease. “Our drive to succeed is fueled by patients and their families, who continue to inspire us as we work to make innovative therapies available as quickly and efficiently as possible.”
http://www.businesswire.com/news/home/20171012005466/en/Aurinia-Receives-National-Corporate-Visionary-Award-Lupus
It's misleading because they've shrunk the volume for that calculation.
They could cover in 2 days or less when the volume last seen back in April and May revisits us.
"....between January and April 2016."
Correction: should be 2017
You're comparing apples to oranges.
The $10 target is short term (12 months), the $40 target is long term and is based on Phase III approval.
The Seaport analyst (Vernon Bernardino) used to work for FBR, where he had periodically issued price targets from $9 to $11 between January and April 2016.
You might want to lighten up and calm down. You're only talking a few pennies, so if you have all of 100 shares you're only down $10 on a ten cent move- and that's only on paper- you don't lose if you don't sell.
When AUPH starts moving in dollars it will be worth getting excited about.
Indeed
You're just speculating (again)
Take heart and fear not. The next bullish Motley Fool article is probably in the works right now.
"Why Aurinia Pharmaceuticals Could Be a Gold Mine for Growth Investors"
A MF article today- largely a rehash but should reach some new readers who are unaware of this exciting story.
https://www.fool.com/investing/2017/09/27/why-aurinia-pharmaceuticals-could-be-a-gold-mine-f.aspx
Fully diluted (warrants, etc.) I think the # is 106M
Would be nice if that holds
But if they raised $$$ at a much higher price, that might not be bad
I can't see any reason yet not to trust Dr. Glickman- this team clearly has integrity
GLTA
Thanks much! You never disappoint!
Good question. I assumed the site doesn't open without pts.
Someone here has to know- probably luna
72 sites enrolled at average 1.6 pts per site = 115 enrolled
Looks great, maybe even ahead of schedule
Only 4 months into it
They have the very best running the trial
Re geography- I hear the salmon from the East River and the Hudson is really quite terrible.
You really want it from Nova Scotia
No worries- I believe the ham will be kosher as well as carbuncle free
Mark your calendar- Grandma out of jail on
09/24/2017 09:55:05 AM
http://investorshub.advfn.com/boards/profilea.aspx?user=206979
The good thing is he is super positive on AUPH
Maybe he will post something new
"....utter nonsense and just guesses"
Give it up- it's hopeless
misleading/inaccurate as usual. You forgot to add from the same source: "The 12-month average price target stands at $11.25, making a nearly 56% upside from where the stock is currently trading.'
The truth will set you free.
Nope- it's really the constant lying, misrepresentation, stupidity, etc. that is annoying
Maciste- BTW, congrats on the Indians- 20 straight!
Simply amazing! Have always loved Terry!
Good luck the rest of the way!
A very frightening thought! I applaud your courage!
And another Canaccord analyst said this in March:
"For Canaccord analyst John Newman, these results are clearly “a significant positive” that have him cheering the tolerability of the drug as one that will just keep getting better as time passes. Therefore, staunchly bullish on the biotech firm’s future, the analyst reiterates a Buy rating on AUPH with a price target of $10, which represents a 62% increase from current levels."
https://www.smarteranalyst.com/2017/03/02/canaccord-applauds-aurinia-pharmaceuticals-inc-auph-shares-shatter-roof-66/
TC- per usual, carb issued misleading/incorrect info
"Canaccord Genuity assumes coverage on Aurinia Pharmaceuticals (NASDAQ: AUPH) with a Spec. Buy rating and a price target of $10.00.
Analyst Neil Maruoka says the company is exposed to the high risks that come with biotech drug development. The analyst believes the company's AURORA drug has a good chance of success (65%) which is "higher than historically seen in other Phase III trials for autoimmune disease." Maruoka also sees the company as an attractive candidate for partnering noting "its positioning as an add-on therapy and potential synergy with the current standard of care, we believe voclosporin represents an attractive partnering opportunity."
https://www.streetinsider.com/Analyst+Comments/Canaccord+Genuity+Assumes+Aurinia+Pharmaceuticals+%28AUPH%29+at+Spec.+Buy%2C+Sees+Co.+As+Attractive+Partnering+Candidate/13290384.html
SvsB: I'm wondering if we're missing a potential windfall
No one bats 1000% but carb is fairly close (nearly always wrong)
Wondering if a small fortune couldn't readily be made by just doing the opposite of every trade idea he has?
You are most welcome! What a joy to see genuine, quality research! Ron is extremely talented, to say the least!
Now this is exciting! From Ron Liu
https://seekingalpha.com/article/4104891-aurinia-pharmaceuticals-patent-analysis-interview-coo
"We got a bounce I've been waiting for.. "
How could you be expecting a bounce? Did you forget you're buying PUTS?
"Polar Capital Steps Into Aurinia Pharmaceuticals Inc (AUPH)..."
"Aurinia is glimmering with solid potential from where Rochussen surveys from Polar Capital, inciting the hedge fund to seize a new holding of 1,183,272 shares worth $7,253,000."
https://www.smarteranalyst.com/2017/08/31/polar-capital-steps-aurinia-pharmaceuticals-inc-auph-kite-pharma-inc-kite-gives-bluebird-bio-inc-blue-axe/
I was way off re full enrollment target date- bad math.
The current pace toward full enrollment is on track to complete within 11 months (from May 17th initiation, assuming 1.6 pts per site); so by April 18th 2018 or thereabouts.
Bottom line is that faster and bigger AUPH expenses are an extremely positive sign and not the negative that has been incorrectly portrayed in some quarters here.
Onward and upward toward completion of P3
"...they added one more site 63."
If only one patient per site they're averaging 18 pts/month so would be fully enrolled by January 2019 at the latest- probably much sooner.